CN106470992A - 作为pi3k抑制剂的吡啶并[1,2‑a]嘧啶酮类似物 - Google Patents

作为pi3k抑制剂的吡啶并[1,2‑a]嘧啶酮类似物 Download PDF

Info

Publication number
CN106470992A
CN106470992A CN201580027396.1A CN201580027396A CN106470992A CN 106470992 A CN106470992 A CN 106470992A CN 201580027396 A CN201580027396 A CN 201580027396A CN 106470992 A CN106470992 A CN 106470992A
Authority
CN
China
Prior art keywords
alkyl
compound
group
optionally
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201580027396.1A
Other languages
English (en)
Other versions
CN106470992B (zh
Inventor
吴成德
于涛
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54934872&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN106470992(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from CN201410271282.9A external-priority patent/CN105461711B/zh
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of CN106470992A publication Critical patent/CN106470992A/zh
Application granted granted Critical
Publication of CN106470992B publication Critical patent/CN106470992B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)

Abstract

公开了一类作为PI3K抑制剂的吡啶并[1，2‑a]嘧啶酮类似物，具体涉及式(I)所示化合物或其药学上可接受的盐。

Description

PCT国内申请，说明书已公开。

Claims (12)

  1. PCT国内申请，权利要求书已公开。
CN201580027396.1A 2014-06-17 2015-06-16 作为pi3k抑制剂的吡啶并[1,2-a]嘧啶酮类似物 Active CN106470992B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201410271282.9A CN105461711B (zh) 2014-06-17 2014-06-17 作为PI3K抑制剂的吡啶并[1,2-a]嘧啶酮类似物
CN2014102712829 2014-06-17
CN201510324348 2015-06-12
CN2015103243480 2015-06-12
PCT/CN2015/081518 WO2015192760A1 (zh) 2014-06-17 2015-06-16 作为pi3k抑制剂的吡啶并［1，2-a］嘧啶酮类似物

Publications (2)

Publication Number Publication Date
CN106470992A true CN106470992A (zh) 2017-03-01
CN106470992B CN106470992B (zh) 2018-11-06

Family

ID=54934872

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580027396.1A Active CN106470992B (zh) 2014-06-17 2015-06-16 作为pi3k抑制剂的吡啶并[1,2-a]嘧啶酮类似物

Country Status (11)

Country Link
US (1) US9856256B2 (zh)
EP (1) EP3159341B8 (zh)
JP (1) JP6680774B2 (zh)
KR (1) KR102495840B1 (zh)
CN (1) CN106470992B (zh)
AU (1) AU2015276699B2 (zh)
CA (1) CA2951971A1 (zh)
EA (1) EA032642B1 (zh)
ES (1) ES2754264T3 (zh)
TW (1) TWI628180B (zh)
WO (1) WO2015192760A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113316575A (zh) * 2019-01-24 2021-08-27 江苏奥赛康药业有限公司 作为TGF-βR1激酶抑制剂的5-(4-吡啶氧基)吡唑类化合物

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180095565A (ko) * 2015-12-16 2018-08-27 치아타이 티안큉 파마수티컬 그룹 주식회사 피리도[1,2-a]피리미돈 유사체, 이의 결정형, 이의 중간체 및 이의 제조방법
CN110386932A (zh) * 2018-04-20 2019-10-29 艾科思莱德制药公司 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
MX2022006700A (es) 2019-12-02 2022-09-02 Storm Therapeutics Ltd Compuestos poliheterociclicos como inhibidores de mettl3.
US20230132982A1 (en) 2020-02-10 2023-05-04 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Use of pyrido[1,2-a]pyrimidinone compound in treating lymphoma
CN115135649A (zh) * 2020-03-10 2022-09-30 正大天晴药业集团股份有限公司 包括吡啶并[1,2-a]嘧啶酮化合物的药物组合
CA3194730A1 (en) * 2020-09-15 2022-03-24 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Use of pyrido[1,2-a]pyrimidinone compound in treating peripheral t cell lymphoma
CN116761608A (zh) * 2020-12-08 2023-09-15 正大天晴药业集团股份有限公司 吡啶并[1,2-a]嘧啶酮化合物的治疗妇科肿瘤的用途
CN118510518A (zh) * 2022-03-09 2024-08-16 正大天晴药业集团股份有限公司 包括吡啶并[1,2-a]嘧啶酮化合物和EGFR抑制剂的药物组合

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100311736A1 (en) * 2007-10-22 2010-12-09 Glaxosmithkline Llc Pyridosulfonamide derivatives as p13 kinase inhibitors
US20110092504A1 (en) * 2008-05-30 2011-04-21 Amgen Inc. Inhibitors of pi3 kinase
CN103224496A (zh) * 2011-11-17 2013-07-31 山东轩竹医药科技有限公司 三环类PI3K和/或mTOR抑制剂
CN103539777A (zh) * 2012-07-13 2014-01-29 广东东阳光药业有限公司 Pi3激酶调节剂及其使用方法和用途
WO2014022128A1 (en) * 2012-07-29 2014-02-06 Calitor Sciences, Llc Pi3 kinase modulators and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004008098T8 (de) 2003-10-10 2008-04-17 Pfizer Products Inc., Groton Substituierte 2h-[1,2,4]triazolo[4,3-a]pyrazine als gsk-3-inhibitoren
ES2431466T3 (es) * 2006-06-30 2013-11-26 Sunesis Pharmaceuticals, Inc. Inhibidores de piridinonil pdk1
MX2012015096A (es) * 2010-07-02 2013-05-28 Gilead Sciences Inc Compuestos heterociclicos fusionados como moduladores del canal ion.
WO2012037108A1 (en) * 2010-09-13 2012-03-22 Glaxosmithkline Llc Aminoquinoline derivatives as antiviral agents
TW201443037A (zh) * 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
JP6386177B2 (ja) * 2014-06-17 2018-09-05 ツーセン ファーマシューティカル カンパニー リミテッド ｍＴＯＲ／ＰＩ３Ｋ阻害剤としてのピリド［１，２−ａ］ピリミジノン類似体

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100311736A1 (en) * 2007-10-22 2010-12-09 Glaxosmithkline Llc Pyridosulfonamide derivatives as p13 kinase inhibitors
US20110092504A1 (en) * 2008-05-30 2011-04-21 Amgen Inc. Inhibitors of pi3 kinase
CN103224496A (zh) * 2011-11-17 2013-07-31 山东轩竹医药科技有限公司 三环类PI3K和/或mTOR抑制剂
CN103539777A (zh) * 2012-07-13 2014-01-29 广东东阳光药业有限公司 Pi3激酶调节剂及其使用方法和用途
WO2014022128A1 (en) * 2012-07-29 2014-02-06 Calitor Sciences, Llc Pi3 kinase modulators and methods of use

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113316575A (zh) * 2019-01-24 2021-08-27 江苏奥赛康药业有限公司 作为TGF-βR1激酶抑制剂的5-(4-吡啶氧基)吡唑类化合物
CN113316575B (zh) * 2019-01-24 2022-03-18 江苏奥赛康药业有限公司 作为TGF-βR1激酶抑制剂的5-(4-吡啶氧基)吡唑类化合物

Also Published As

Publication number Publication date
AU2015276699B2 (en) 2019-10-10
TWI628180B (zh) 2018-07-01
CA2951971A1 (en) 2015-12-23
EP3159341B8 (en) 2020-01-08
EP3159341A4 (en) 2018-05-16
JP2017519821A (ja) 2017-07-20
EP3159341A1 (en) 2017-04-26
US20170137420A1 (en) 2017-05-18
AU2015276699A1 (en) 2017-01-19
JP6680774B2 (ja) 2020-04-15
EP3159341B1 (en) 2019-08-21
KR102495840B1 (ko) 2023-02-03
EA032642B1 (ru) 2019-06-28
CN106470992B (zh) 2018-11-06
TW201625612A (zh) 2016-07-16
EA201790016A1 (ru) 2017-06-30
WO2015192760A1 (zh) 2015-12-23
ES2754264T3 (es) 2020-04-16
US9856256B2 (en) 2018-01-02
KR20170016465A (ko) 2017-02-13

Similar Documents

Publication Publication Date Title
CN106470992A (zh) 作为pi3k抑制剂的吡啶并[1,2‑a]嘧啶酮类似物
CN105121432B (zh) 作为激酶抑制剂的杂环酰胺
CN105228997B (zh) Carm1抑制剂及其用途
CN104837825B (zh) 鲁顿酪氨酸激酶抑制剂
US10138256B2 (en) MK2 inhibitors and uses thereof
ES2626006T3 (es) Derivados de 6-cicloalquil-1,5-dihidro-pirazolo[3,4-d]pirimidin-4-ona y su uso como inhibidores de PDE9A
CN112955459A (zh) 双环肽配体和其用途
AU2017203272A1 (en) Inhibitors of LRRK2 kinase activity
CN103002897A (zh) 特定氨基-哒嗪类，与其组合物，及其使用方法
CN105461711B (zh) 作为PI3K抑制剂的吡啶并[1,2-a]嘧啶酮类似物
CN102361859A (zh) 用作Raf激酶抑制剂的杂芳基化合物
CN109661396A (zh) 作为rock抑制剂的螺稠合环状脲
CN101878031A (zh) 用于治疗骨髓增生性疾病和其他增生性疾病的激酶抑制剂
TW201414736A (zh) 作爲ＬＲＲＫ２抑制劑之新穎４－（經取代胺基）－７Ｈ－吡咯并［２，３－ｄ］嘧啶類
JP2020514361A (ja) ９，１０，１１，１２−テトラヒドロ−８ｈ−［１，４］ジアゼピノ［５’，６’：４，５］チエノ［３，２−ｆ］キノリン−８−オン化合物およびその使用
CN103476776B (zh) 作为FAK/Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物
WO2019034128A1 (zh) 吡咯并三嗪类衍生物、其制备方法及其用途
CN109415341A (zh) 作为TGF-βR1抑制剂的苯并三氮唑衍生的α，β不饱和酰胺类化合物
TW200902011A (en) Novel pyrimidine compounds having benzyl (heterocyclic metyly) amine structure and medicament comprising the same
CN104837490A (zh) 作为无义突变抑制子的嘧啶并[4,5-b]喹啉-4,5(3H,10H)-二酮
CN107438598A (zh) 喹唑啉和喹啉化合物及其用途
CN107406427A (zh) 炔基醇及其使用方法
CN114401955A (zh) 细胞周期蛋白依赖性激酶的抑制剂
WO2020156283A1 (zh) 炔基嘧啶或炔基吡啶类化合物、及其组合物与应用
WO2019134661A1 (zh) 异吲哚啉酮及其衍生物作为csf-1r抑制剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1238629

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CP02 Change in the address of a patent holder

Address after: No. 369, Yuzhou South Road, Lianyungang, Jiangsu Province

Patentee after: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Address before: 222062 Yuzhou South Road, Haizhou District, Lianyungang, Jiangsu 369

Patentee before: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

CP02 Change in the address of a patent holder